
AbbVie (ABBV) Stock Forecast & Price Target
AbbVie (ABBV) Analyst Ratings
Bulls say
AbbVie is poised for strong performance, supported by a diverse portfolio that includes pharmaceuticals, immunology, and aesthetics products. Recent acquisitions, such as Allergan, Cerevel, and ImmunoGen, have supplemented the company's portfolio and provide potential for future growth. The company's 1Q 2026 earnings were inline, with revenue and earnings in line with AbbVie's guidance. Guggenheim has raised revenue estimates, primarily driven by increased sales estimates for Rinvoq and Skyrizi, and has increased its DCF-derived price target on ABBV shares to $249/share. While there may be concerns about Skyrizi and Rinvoq's longer-term growth, AbbVie's strong performance and potential pipeline developments suggest high single-digit topline growth through the decade.
Bears say
AbbVie is a pharmaceutical company that reported solid 1Q 2026 results with total net revenues of $15.00Bn and adjusted EPS of $2.65, both of which exceeded estimates. The company raised their FY 2026 revenue and EPS guidance, and showed promising data for their pipeline programs in multiple therapeutic areas. However, there are downside risks, such as potential pricing and competition risks for key products, and the potential impact of tariffs and taxes on the company's low tax rate. Additionally, the forecasted growth of their aesthetics franchise has been lowered.
This aggregate rating is based on analysts' research of AbbVie and is not a guaranteed prediction by Public.com or investment advice.
AbbVie (ABBV) Analyst Forecast & Price Prediction
Start investing in AbbVie (ABBV)
Order type
Buy in
Order amount
Est. shares
0 shares